Aomar-Millán, Ismael FranciscoSalvatierra, JuanTorres-Parejo, ÚrsulaNuñez-Nuñez, MaríaHernández-Quero, JoséAnguita-Santos, Francisco2023-02-092023-02-092021-01-28http://hdl.handle.net/10668/17226To assess clinical outcomes according to the immunosuppressive treatment administered to patients with severe SARS-CoV-2 pneumonia and moderate inflammation. A retrospective observational cohort study involving 142 patients with severe COVID-19 pneumonia and moderate inflammation divided into three treatment groups (pulses of methylprednisolone alone [groupI], tocilizumab alone [groupII] and methylprednisolone plus tocilizumab [groupIII]). The aim was to assess intergroups differences in the clinical course with a 60-day follow-up and related analytical factors. 14 patients (9,8%) died: 8 (10%) in groupI and 6 (9,5%) in groupsII andIII. 15 (10,6%) were admitted to ICU: 2 (2,5%) from groupI, 4 (28,5%) from groupII and 9 (18,4%) from groupIII. The mean hospital stay was longer in groupII and clinical outcome was not associated with treatment. Tocilizumab seems to be not associated with better clinical outcomes and should be reserved for clinical trial scenario, since its widespread use may result in higher rate of ICU admission and longer mean hospital stay without differences in mortality rate and potentially adverse events.enCOVID-19Cytokine storm syndromeInflamaciónInflammationMethylprednisoloneMetilprednisolonaSíndrome de tormenta de citoquinasTocilizumabAntibodies, Monoclonal, HumanizedGlucocorticoidsHumansInflammationRetrospective StudiesSARS-CoV-2Treatment OutcomeCOVID-19 Drug Treatmentresearch article33622529open access10.1016/j.medcli.2021.01.0061578-8989PMC7843156https://doi.org/10.1016/j.medcli.2021.01.006https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843156/pdf